Trial | NCT00461422  Report issue

Title

Early Follicular Supplementation of Ganirelix in IVF 2004
Early Follicular GnRH Antagonist Supplementation Improves Fertilization and Embryo Cleavage Rates in IVF-ET GnRH Antagonist Cycles

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ganirelix ...

  • Study Participants

    50
Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results
GnRH antagonist offers many advantages when used in IVF-ET treatment, however, it is suspected to yield lower pregnancy rate when compared with the long GnRH agonist protocol.

Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results.

Consecutive patients are prospectively enrolled and randomly assigned to the study and control groups. Patients with low ovarian reserve or with uterine distortion are excluded from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group are also treated with additional GnRH antagonist 0.25 mg/day on day 1, 2 and 3 of the menstrual cycle.
Study Started
Jan 31
2004
Primary Completion
Jun 30
2007
Study Completion
Jun 30
2007
Last Update
Jun 27
2008
Estimate

Drug Ganirelix

sc injection of Ganirelix 0.25 mg per day

1 Experimental

Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle

2 No Intervention

Standard Flexible antagonist protocol

Criteria 

Inclusion Criteria:

infertility
IVF candidate
failure of previous IVF attempt

Exclusion Criteria:

low ovarian reserve
untreated distortion of uterine cavity
medical contraindication for IVF treatment
No Results Posted